{"id":"jak2","name":"JAK2","symbol":"JAK2","route":"/targets/jak2/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6192","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000096968","uniprot":"https://www.uniprot.org/uniprotkb/O60674/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/O60674","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2971","open-targets":"https://platform.opentargets.org/target/ENSG00000096968","civic":"https://civicdb.org/genes/3717/summary","oncokb":"https://www.oncokb.org/gene/JAK2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=JAK2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=JAK2","depmap":"https://depmap.org/portal/gene/JAK2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000096968-JAK2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3717","omim":"https://www.omim.org/entry/147796"}],"products":[{"id":"fedratinib","name":"Fedratinib","status":"approved","modality":"Small-molecule JAK2/FLT3 inhibitor","route":"/drugs/fedratinib/"},{"id":"inca033989","name":"INCA033989","status":"phase-1","modality":"Monoclonal antibody against mutant calreticulin","route":"/drugs/inca033989/"},{"id":"momelotinib","name":"Momelotinib","status":"approved","modality":"Small-molecule JAK1/JAK2/ACVR1 inhibitor","route":"/drugs/momelotinib/"},{"id":"pacritinib","name":"Pacritinib","status":"approved","modality":"Small-molecule JAK2/IRAK1/ACVR1 inhibitor","route":"/drugs/pacritinib/"},{"id":"ropeginterferon-alfa-2b","name":"Ropeginterferon alfa-2b","status":"approved","modality":"Long-acting mono-pegylated interferon alfa","route":"/drugs/ropeginterferon-alfa-2b/"},{"id":"ruxolitinib","name":"Ruxolitinib","status":"approved","modality":"Small-molecule JAK1/JAK2 inhibitor","route":"/drugs/ruxolitinib/"}],"trials":[{"id":"manifest-2","name":"MANIFEST-2","nct":"NCT04603495","phase":"3","status":"mixed"},{"id":"momentum","name":"MOMENTUM","nct":"NCT04173494","phase":"3","status":"positive"},{"id":"proud-pv","name":"PROUD-PV and CONTINUATION-PV","nct":"NCT01949805","phase":"3","status":"positive"},{"id":"response-2","name":"RESPONSE-2","nct":"NCT02038036","phase":"3","status":"positive"},{"id":"response","name":"RESPONSE","nct":"NCT01243944","phase":"3","status":"positive"},{"id":"comfort-i","name":"COMFORT-I","nct":"NCT00952289","phase":"3","status":"positive"},{"id":"comfort-ii","name":"COMFORT-II","nct":"NCT00934544","phase":"3","status":"positive"},{"id":"pt-1","name":"PT-1 (Primary Thrombocythaemia 1)","phase":"3","status":"positive"},{"id":"nct05481151","name":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","nct":"NCT05481151","phase":"3","status":"active"},{"id":"nct04655092","name":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","nct":"NCT04655092","phase":"3","status":"recruiting"},{"id":"nct06468033","name":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","nct":"NCT06468033","phase":"3","status":"active"},{"id":"nct04285086","name":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","nct":"NCT04285086","phase":"3","status":"active"},{"id":"nct04562389","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","nct":"NCT04562389","phase":"3","status":"active"},{"id":"nct04543279","name":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","nct":"NCT04543279","phase":"2"},{"id":"majic-pv","name":"MAJIC-PV","phase":"2","status":"positive"},{"id":"low-pv","name":"Low-PV","nct":"NCT03003325","phase":"2","status":"positive"},{"id":"keynote-170","name":"KEYNOTE-170","nct":"NCT02576990","phase":"2","status":"positive"},{"id":"majic-et","name":"MAJIC-ET","phase":"2","status":"negative"},{"id":"nct05482971","name":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","nct":"NCT05482971","phase":"2","status":"active"},{"id":"nct05485948","name":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","nct":"NCT05485948","phase":"2","status":"active"},{"id":"aall1521","name":"AALL1521","nct":"NCT02723994","phase":"2","status":"completed"},{"id":"nct02955940","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","nct":"NCT02955940","phase":"2","status":"active"},{"id":"nct03669965","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","nct":"NCT03669965","phase":"2","status":"active"},{"id":"nct07033598","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","nct":"NCT07033598","phase":"2","status":"recruiting"},{"id":"nct04509700","name":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","nct":"NCT04509700","phase":"2","status":"active"},{"id":"nct04817007","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","nct":"NCT04817007","phase":"1/2","status":"active"},{"id":"nct07219576","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","nct":"NCT07219576","phase":"1/2","status":"recruiting"}],"pathways":["chemical-carcinogenesis-receptor-activation","caf-activation-desmoplasia","pancreatic-cancer-signalling"],"companies":["aop-health","bms","gsk","incyte","novartis","sobi"],"keyPapers":["paper-momentum-momelotinib-lancet-2023","paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","paper-kralovics-n-engl-j-med","paper-darnell-jak-stat-science-1994"],"hotspots":[{"label":"V617F","position":617,"kind":"activating","frequency":"About 95% of polycythaemia vera and 50 to 60% of essential thrombocythaemia and primary myelofibrosis","drugs":["ruxolitinib","fedratinib","momelotinib","pacritinib","ropeginterferon-alfa-2b"]},{"label":"Exon 12 (N542_E543del, K539L)","position":540,"kind":"activating","frequency":"About 3% of polycythaemia vera","drugs":["ruxolitinib","ropeginterferon-alfa-2b"]}],"openQuestions":[],"assays":[],"resistance":[{"class":"pd1-hodgkin","mechanism":"Low-level 9p24.1 gain","category":"other"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}